biostudies-literatureUnknown11(6)Jalbert JJRegeneron Pharmaceuticals<h4>Introduction</h4>Data on real-world effectiveness of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) for the treatment of coronavirus disease 2019 (COVID-19) are limited. The objective of this study was to assess the effectiveness of SC CAS+IMD versus no antibody treatment among patients with COVID-19.<h4>Methods</h4>This retrospective cohort study linked Komodo Health and CDR Maguire Health and Medical data. Patients diagnosed with COVID-19 in ambulatory settings (August 1-October 30, 2021) treated with SC CAS+IMD were exact- and propensity score-matched to fewer than five untreated treatment-eligible patients and followed for the composite endpoint of 30-day all-cause mortality or COVID-19-related hospitalization. Kaplan-Meier estimators were used to calculate outcome risk overInfectious diseases and therapy2125-2139https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526200biostudies-literatureEffectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19.PMC9526200Murdock DWang DJalbert JJHussein MMastey VSanchez RJBussey JHirshberg BWeinreich DMWei WFarinas LDuart CfalseEffectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19.<h4>Introduction</h4>Data on real-world effectiveness of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) for the treatment of coronavirus disease 2019 (COVID-19) are limited. The objective of this study was to assess the effectiveness of SC CAS+IMD versus no antibody treatment among patients with COVID-19.<h4>Methods</h4>This retrospective cohort study linked Komodo Health and CDR Maguire Health and Medical data. Patients diagnosed with COVID-19 in ambulatory settings (August 1-October 30, 2021) treated with SC CAS+IMD were exact- and propensity score-matched to fewer than five untreated treatment-eligible patients and followed for the composite endpoint of 30-day all-cause mortality or COVID-19-related hospitalization. Kaplan-Meier estimators were used to calculate outcome risk over2022-01-01T00:00:00Z2022 Dec2025-04-05T11:40:11.384Z2025-04-05T11:40:11.384ZS-EPMC95262003618163910.1007/s40121-022-00691-z